Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety Meeting Abstract
| Authors: | Bryce, A. H.; McDermott, R. S.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; Lindberg, H.; Morris, D.; Nole, F.; Staffurth, J. N.; Abida, W.; Caunt, L.; Despain, D.; Ryan, C. J.; Fizazi, K.; Chowdhury, S. |
| Abstract Title: | Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454760200047 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.155 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 155 -- Source: Wos |
